1822-32-8

Basic information

• Product Name: 3-PIPERIDIN-4-YL-PROPIONIC ACID
• Synonyms: 3-PIPERIDIN-4-YL-PROPIONIC ACID;3-PIPERIDINE-4-YL-PROPIONIC ACID;RARECHEM AK PQ 0384;Zinc04204051;3-(4-piperidinyl)propanoic acid(SALTDATA: HCl);4-Piperidinepropanoic acid;3-Piperidin-4-yl-propionic acid ethyl ester.HCl;3-(4-piperidinyl)propanoic acid
• CAS NO: 1822-32-8
• Molecular Formula: C₈H₁₅NO₂
• Molecular Weight: 157.21
• Product Categories: pharmacetical
• Mol File: 1822-32-8.mol
• Article Data: 14

Chemical Properties

• Melting Point: 275-277℃
• Boiling Point: 299℃
• Flash Point: 135℃
• Appearance: /
• Density: 1.039
• Vapor Pressure: 0.000284mmHg at 25°C
• Refractive Index: 1.466
• PKA: 4.66±0.10(Predicted)
• CAS DataBase Reference: 3-PIPERIDIN-4-YL-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PIPERIDIN-4-YL-PROPIONIC ACID(1822-32-8)
• EPA Substance Registry System: 3-PIPERIDIN-4-YL-PROPIONIC ACID(1822-32-8)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 1822-32-8(Hazardous Substances Data)

Usage

General Description

3-Piperidin-4-yl-propionic acid, also known as P4PA, is a chemical compound with the molecular formula C9H15NO2. It is a piperidine derivative and a precursor in the synthesis of various pharmaceuticals and organic compounds. P4PA is known for its potential use in pharmaceutical research and drug development due to its ability to modulate various biological pathways and processes. It is also used as a building block in the synthesis of other organic compounds with potential pharmacological activity. P4PA may have potential applications in the development of new drugs for the treatment of various diseases and conditions, and its versatile chemical structure makes it a valuable intermediate in organic synthesis.

InChI:InChI=1/C8H15NO2/c10-8(11)2-1-7-3-5-9-6-4-7/h7,9H,1-6H2,(H,10,11)

Upstream product

• 40500-10-5 3-(tetrahydro-2H-pyran-4-yl)propanoic acid 
• 154775-43-6 3-(1-(tert-butoxycarbonyl)piperidin-4-yl)propanoic acid 
• 5337-79-1 3-(4-pyridinyl)-2-propenoic acid 
• 131417-49-7 3-[1-(acetyl)-4-piperidinyl]propionic acid 
• 123829-75-4 3-pyridin-4ylpropen-2-oic acid 
• 854830-56-1 diethyl 2-((tetrahydro-2H-pyran-4-yl)methyl)malonate 
• 854830-57-2 tetrahydropyran-4-ylmethyl-malonic acid 
• 125552-89-8 4-(bromomethyl)tetrahydro-2H-pyran 
• 98488-12-1 trans-3-(4'-pyridyl)acrylic acid hydrochloride 
• 84228-93-3 3-(pyridin-4-yl)acrylic acid 
• 301232-45-1 tert-butyl 4-(3-ethoxy-3-oxopropyl)-1-piperidinecarboxylate 
• 71879-55-5 ethyl 3-(piperid-4-yl)propionate 

Downstream Products

• 75999-93-8 3-(1-benzoyl 4-piperidyl)-propionic acid 
• 154775-43-6 3-(1-(tert-butoxycarbonyl)piperidin-4-yl)propanoic acid 
• 71879-50-0 methyl 3-(4-piperidinyl)-propionate 
• 71879-55-5 ethyl 3-(piperid-4-yl)propionate 
• 169498-29-7 (R)-1-[3-(1-benzyloxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylic acid 
• 198958-88-2 [S-(R*,S*)]-β-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid 

Relevant articles and documents

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial

NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS

The invention concerns a compound of formula (I), wherein Y represents a macrocycle whereof the cycle comprises 9 to 36 atoms, and is functionalized by three amine or COOH functions; Rc represents a group of formula H—Xa—Xb—Xc—Xd—Xe—(Xf)i—, wherein i represents 0 or 1, Xn is in particular selected among lysine, arginine, ornithine residues, Xb is in particular selected among glycine, asparagine, L-proline or D-proline residues, Xc et Xd are in particular selected among tyrosine, phenylalanine or 3-nitrotyrosine residues, Xe et Xf are in particular selected among the following amino acid residues: NH2—(CH2)n—COOH, n ranging from 1 to 10 or NH2—(CH2—CH2—O)m—CH2CH2COOH, m ranging from 3 to 6, provided that one at least of the amino acid residues Xa, Xb, Xc and Xd is different from the corresponding amino acid in the sequence of the natural CD40 143Lys-Gly-Tyr-Tyr146 fragment

Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)

A series of 3-mercapto-propionic acid derivatives that function as reversible inhibitors of carboxypeptidase U have been prepared. We present a successful design strategy using cyclic, low basicity guanidine mimetics resulting in potent, selective and bioavailable inhibitors of carboxypeptidase U (TAFIa).